Format

Send to

Choose Destination
Int J Biol Sci. 2012;8(1):59-65. Epub 2011 Nov 18.

EZH2 methyltransferase and H3K27 methylation in breast cancer.

Author information

1
Laboratory of Genetics and Physiology, National Institutes of Health, Bethesda, MD 20892, USA. ryuk@mail.nih.gov

Abstract

Histone modifications are thought to control the regulation of genetic programs in normal physiology and cancer. Methylation (mono-, di-, and tri-methylation) on histone H3 lysine (K) 27 induces transcriptional repression, and thereby participates in controlling gene expression patterns. Enhancer of zeste (EZH) 2, a methyltransferase and component of the polycomb repressive complex 2 (PRC2), plays an essential role in the epigenetic maintenance of the H3K27me3 repressive chromatin mark. Abnormal EZH2 expression has been associated with various cancers including breast cancer. Here, we discuss the contribution of EZH2 and the PRC2 complex in controlling the H3K27 methylation status and subsequent consequences on genomic instability and the cell cycle in breast cancer cells. We also discuss distinct molecular mechanisms used by EZH2 to suppress BRCA1 functions.

KEYWORDS:

BRCA1; Breast cancer; EZH2; H3K27 methylation

PMID:
22211105
PMCID:
PMC3226033
DOI:
10.7150/ijbs.8.59
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center